Table 3.
Multivariable models for the FAIN and overall survival.
| Overall population, HR (95%CI), cases/events = 14,134/3,241 | Sensitivity analysis, HR (95%CI) | ||||||
|---|---|---|---|---|---|---|---|
| Models | Model 1a | Model 2b | Model 3c | Model 4d | Model 5e | Model 6f | Model 7g |
| FAIN, continuous | 0.21 (0.18–0.24) | 0.23 (0.19–0.26) | 0.51 (0.43–0.61) | 0.57 (0.47–0.68) | 0.67 (0.55–0.82) | 0.67 (0.54–0.84) | 0.68 (0.52–0.89) |
| FAIN, per 1 SD (0.3) | 0.59 (0.56–0.62) | 0.61 (0.57–0.64) | 0.80 (0.75–0.85) | 0.83 (0.78–0.88) | 0.87 (0.82–0.93) | 0.88 (0.81–0.94) | 0.88 (0.80–0.96) |
| FAIN, OS, high vs. low | 0.42 (0.39–0.46) | 0.47 (0.43–0.52) | 0.71 (0.64–0.78) | 0.71 (0.64–0.78) | 0.71 (0.64–0.78) | 0.71 (0.64–0.78) | 0.86 (0.74–0.99) |
| FAIN, high vs. lowh | 0.44 (0.41–0.48) | 0.50 (0.46–0.54) | 0.74 (0.68–0.81) | 0.78 (0.71–0.86) | 0.85 (0.77–0.94) | 0.88 (0.79–0.98) | 0.89 (0.78–1.03) |
| FAIN, tertile | |||||||
| Tertile 1 | Reference | Reference | Reference | Reference | Reference | Reference | Reference |
| Tertile 2 | 0.65 (0.60–0.70) | 0.67 (0.62–0.72) | 0.84 (0.77–0.91) | 0.86 (0.79–0.94) | 0.92 (0.84–1.01) | 0.92 (0.84–1.01) | 0.96 (0.84–1.10) |
| Tertile 3 | 0.32 (0.29–0.35) | 0.35 (0.31–0.39) | 0.61 (0.54–0.69) | 0.65 (0.58–0.74) | 0.73 (0.64–0.84) | 0.73 (0.64–0.84) | 0.79 (0.65–0.95) |
| FAIN, quartile | |||||||
| Quartile 1 | Reference | Reference | Reference | Reference | Reference | Reference | Reference |
| Quartile 2 | 0.74 (0.68–0.81) | 0.75 (0.69–0.81) | 0.86 (0.79–0.94) | 0.88 (0.81–0.97) | 0.92 (0.83–1.02) | 0.89 (0.79–0.99) | 0.89 (0.77–1.03) |
| Quartile 3 | 0.50 (0.46–0.55) | 0.51 (0.47–0.57) | 0.74 (0.66–0.82) | 0.78 (0.70–0.87) | 0.86 (0.77–0.97) | 0.88 (0.77–1.00) | 0.89 (0.75–1.05) |
| Quartile 4 | 0.28 (0.25–0.31) | 0.29 (0.25–0.33) | 0.54 (0.47–0.63) | 0.59 (0.51–0.68) | 0.65 (0.55–0.76) | 0.63 (0.53–0.76) | 0.68 (0.54–0.85) |
| FAIN, quintile | |||||||
| Quintile 1 | Reference | Reference | Reference | Reference | Reference | Reference | Reference |
| Quintile 2 | 0.81 (0.74–0.89) | 0.81 (0.74–0.89) | 0.89 (0.81–0.98) | 0.91 (0.82–1.00) | 0.95 (0.85–1.05) | 0.92 (0.81–1.03) | 0.88 (0.76–1.03) |
| Quintile 3 | 0.63 (0.57–0.69) | 0.63 (0.57–0.70) | 0.82 (0.73–0.91) | 0.85 (0.76–0.95) | 0.91 (0.80–1.02) | 0.92 (0.81–1.05) | 0.90 (0.76–1.07) |
| Quintile 4 | 0.42 (0.38–0.47) | 0.43 (0.38–0.48) | 0.66 (0.58–0.75) | 0.70 (0.62–0.80) | 0.81 (0.70–0.93) | 0.83 (0.71–0.97) | 0.82 (0.67–0.99) |
| Quintile 5 | 0.25 (0.22–0.28) | 0.25 (0.22–0.30) | 0.51 (0.43–0.60) | 0.55 (0.46–0.65) | 0.61 (0.51–0.73) | 0.63 (0.51–0.77) | 0.60 (0.46–0.77) |
HR (95%CI), hazard ratio (95% confidence interval); FAIN, the fat-age-inflammation index; SD, standard deviation; OS, optimal stratification.
Model 1 is the unadjusted crude model.
Model 2 is adjusted for the age at baseline (continuous).
Model 3 is adjusted for the age at baseline (continuous), sex (reference = female), tumor stage (reference = I), radical surgery (reference = no), curative chemotherapy (reference = no), pre-albumin (continuous), handgrip strength (continuous), the Nutritional Risk Screening 2002 (reference = <3), length of hospital stay (continuous) and cancer type (reference = lung cancer).
Model 4 is adjusted for all variables in Model 3, plus the calf circumference (continuous), Patient-Generated Subjective Global Assessment score (reference = 0–1), Karnofsky Performance Status score (continuous) and the global quality of life score (continuous).
Model 5 is adjusted for all covariates in Model 4, but excluded the patients who died within the first 3 months after enrollment (cases/events = 13,626/2,734).
Model 6 is adjusted for all covariates in Model 4, but excluded the patients who died within the first 6 months after enrollment (cases/events = 13,125/2,236).
Model 7 is adjusted for all covariates in Model 4, but excluded the patients who died within the first 12 months after enrollment (cases/events = 12,039/1,388).
High, ≥median (0.77); low, < median (0.77).